- Community-Beiträge
- Aktuellste Threads
| Geld/Brief | 16,47 $ / 37,10 $ |
| Spread | +125,26% |
| Schluss Vortag | 24,71 $ |
| Gehandelte Stücke | 27.278 |
| Tagesvolumen Vortag | 173.803,5 $ |
| Tagestief 22,71 $ Tageshoch 24,70 $ | |
| 52W-Tief 8,00 $ 52W-Hoch 35,00 $ | |
| Jahrestief 16,92 $ Jahreshoch 35,00 $ | |
| Handelsplatz | Letzter | Änderung | Vortag | Zeit | |
|---|---|---|---|---|---|
| NYSE | 23,02 $ | - | - | 02.06.26 | |
| Nasdaq | 23,145 $ | -6,33% | 24,71 $ | 02.06.26 | |
| AMEX | 25,07 $ | - | - | 29.05.26 | |
| Datum | Kurs | Volumen |
|---|---|---|
| 01.06.26 | 24,92 | 174 T |
| 29.05.26 | 26,21 | 1,07 M |
| 28.05.26 | 26,16 | 88 T |
| 27.05.26 | 26,46 | 123 T |
| 26.05.26 | 26,17 | 102 T |
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Woche | 26,17 $ | -4,55% |
| 1 Monat | 33,60 $ | -25,65% |
| 6 Monate | 15,54 $ | +60,75% |
| 1 Jahr | 8,14 $ | +206,88% |
| 5 Jahre | - | - |
| Aktientyp | Stammaktie |
Zahlen für Q2/23
-SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers continues to enroll with safety data expected by the end of 2023
-SZN-1326 Phase 1a clinical trial in healthy volunteers continues to enroll with safety data expected by the end of 2023
-Corporate prioritization efforts expected to provide cash runway extension into 2025
https://investors.surrozen.com/news-releases/news-release-details/surrozen-provides-second-quarter-2023-financial-results
Zahlen für Q1/23
- cash runway into the second half of 2024
- SZN-043 Phase 1a with safety data expected by the end of 2023
- SZN-1326 Phase 1a with safety data expected by the end of 2023
https://investors.surrozen.com/news-releases/news-release-details/surrozen-provides-first-quarter-2023-financial-results-and
Mit Cash für ca. 4 Quartalen könnten sich die beiden Katalysatoren in Q4 noch gut mitnehmen lassen.
